Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines

Overview

Journal Mol Cell Proteomics

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2022 Jul 21

PMID 35863698

Authors

Iris E Glykofridis

Alex A Henneman

Jesper A Balk

Richard Goeij-de Haas

Denise Westland

Sander R Piersma

Jaco C Knol

Thang V Pham

Michiel Boekhout

Fried J T Zwartkruis

Rob M F Wolthuis

Connie R Jimenez

Affiliations

Soon will be listed here.

Abstract

In Birt-Hogg-Dubé (BHD) syndrome, germline loss-of-function mutations in the Folliculin (FLCN) gene lead to an increased risk of renal cancer. To address how FLCN inactivation affects cellular kinase signaling pathways, we analyzed comprehensive phosphoproteomic profiles of FLCN and FLCN human renal tubular epithelial cells (RPTEC/TERT1). In total, 15,744 phosphorylated peptides were identified from 4329 phosphorylated proteins. INKA analysis revealed that FLCN loss alters the activity of numerous kinases, including tyrosine kinases EGFR, MET, and the Ephrin receptor subfamily (EPHA2 and EPHB1), as well their downstream targets MAPK1/3. Validation experiments in the BHD renal tumor cell line UOK257 confirmed that FLCN loss contributes to enhanced MAPK1/3 and downstream RPS6K1/3 signaling. The clinically available MAPK inhibitor Ulixertinib showed enhanced toxicity in FLCN cells. Interestingly, FLCN inactivation induced the phosphorylation of PIK3CD (Tyr524) without altering the phosphorylation of canonical Akt1/Akt2/mTOR/EIF4EBP1 phosphosites. Also, we identified that FLCN inactivation resulted in dephosphorylation of TFEB Ser109, Ser114, and Ser122, which may be linked to increased oxidative stress levels in FLCN cells. Together, our study highlights differential phosphorylation of specific kinases and substrates in FLCN renal cells. This provides insight into BHD-associated renal tumorigenesis and may point to several novel candidates for targeted therapies.

References

Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R . A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell Proteomics. 2018; 18(3):576-593. PMC: 6398202. DOI: 10.1074/mcp.TIR118.000943. View

Napolitano G, Di Malta C, Esposito A, de Araujo M, Pece S, Bertalot G . A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome. Nature. 2020; 585(7826):597-602. PMC: 7610377. DOI: 10.1038/s41586-020-2444-0. View

Di Malta C, Siciliano D, Calcagni A, Monfregola J, Punzi S, Pastore N . Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth. Science. 2017; 356(6343):1188-1192. PMC: 5730647. DOI: 10.1126/science.aag2553. View

van der Mijn J, Labots M, Piersma S, Pham T, Knol J, Broxterman H . Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. J Proteomics. 2015; 127(Pt B):259-63. DOI: 10.1016/j.jprot.2015.04.006. View

Elbaek C, Petrosius V, Sorensen C . WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat Res. 2020; 819-820:111694. DOI: 10.1016/j.mrfmmm.2020.111694. View

Yang Y, Padilla-Nash H, Vira M, Abu-Asab M, Val D, Worrell R . The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway. Cancer Genet Cytogenet. 2008; 180(2):100-9. PMC: 2440670. DOI: 10.1016/j.cancergencyto.2007.10.010. View

Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J . CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018; 24(7):927-930. DOI: 10.1038/s41591-018-0049-z. View

Schoffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S . Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer. 2017; 87:147-163. DOI: 10.1016/j.ejca.2017.10.014. View

Feener E, Rosario F, Dunn S, Stancheva Z, Myers Jr M . Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol. 2004; 24(11):4968-78. PMC: 416405. DOI: 10.1128/MCB.24.11.4968-4978.2004. View

10.

Halliday B, Fukuzawa R, Markie D, Grundy R, Ludgate J, Black M . Germline mutations and somatic inactivation of TRIM28 in Wilms tumour. PLoS Genet. 2018; 14(6):e1007399. PMC: 6005459. DOI: 10.1371/journal.pgen.1007399. View

11.

Songyang Z, Lu K, Kwon Y, Tsai L, Filhol O, Cochet C . A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol. 1996; 16(11):6486-93. PMC: 231650. DOI: 10.1128/MCB.16.11.6486. View

12.

Hong S, Oh H, Valera V, Baba M, Schmidt L, Linehan W . Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One. 2011; 5(12):e15793. PMC: 3012117. DOI: 10.1371/journal.pone.0015793. View

13.

Baba M, Hong S, Sharma N, Warren M, Nickerson M, Iwamatsu A . Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006; 103(42):15552-7. PMC: 1592464. DOI: 10.1073/pnas.0603781103. View

14.

Laviolette L, Mermoud J, Calvo I, Olson N, Boukhali M, Steinlein O . Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017; 8:15866. PMC: 5493755. DOI: 10.1038/ncomms15866. View

15.

Nickerson M, Warren M, Toro J, Matrosova V, Glenn G, Turner M . Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell. 2002; 2(2):157-64. DOI: 10.1016/s1535-6108(02)00104-6. View

16.

Schulze W, Deng L, Mann M . Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2006; 1:2005.0008. PMC: 1681463. DOI: 10.1038/msb4100012. View

17.

Roczniak-Ferguson A, Petit C, Froehlich F, Qian S, Ky J, Angarola B . The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012; 5(228):ra42. PMC: 3437338. DOI: 10.1126/scisignal.2002790. View

18.

Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X . miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res. 2014; 20(10):2617-30. DOI: 10.1158/1078-0432.CCR-13-3224. View

19.

Goedhart J, Luijsterburg M . VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots. Sci Rep. 2020; 10(1):20560. PMC: 7689420. DOI: 10.1038/s41598-020-76603-3. View

20.

Wildenberg G, Dohn M, Carnahan R, Davis M, Lobdell N, Settleman J . p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell. 2006; 127(5):1027-39. DOI: 10.1016/j.cell.2006.09.046. View